Education
About Us
Working with TipRanks
Follow Us
Xencor Inc (XNCR)
NASDAQ:XNCR
XNCR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$12.54 - $27.24
Previous CloseN/A
Volume126.93K
Average Volume (3M)658.14K
Market Cap
$930.10M
Enterprise Value$828.17M
Total Cash (Recent Filing)$40.88M
Total Debt (Recent Filing)$231.95M
Price to Earnings (P/E)―
Beta1.70
Next Earnings
May 08, 2025EPS Estimate
-0.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.64
Shares Outstanding70,461,940
10 Day Avg. Volume869,437
30 Day Avg. Volume658,144
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)8.42
Price to Cash Flow (P/CF)-4.20
P/FCF Ratio0.00
Enterprise Value/Market Cap0.89
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit7.50
Enterprise Value/Ebitda-4.69
Forecast
1Y Price Target
$29.56Price Target Upside123.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
---
Xencor News
PremiumCompany Announcements
Xencor Appoints Todd Simpson to Board of Directors---
Bulls Say, Bears Say
Bulls Say
Financial PositionXencor ended the quarter with cash and cash equivalents of $707M, providing a cash runway into 2028.
Pipeline And ResearchManagement highlighted the company's emerging pipeline efforts in oncology and immunology.
Program DevelopmentUpdates on -819 and -942 could provide upside for the stock and the current valuation offers an attractive entry point into multiple catalysts expected.
Bears Say
Asset Development DelaysThis shift delays the timeline to commercialization of a wholly-owned asset.
Stock PerformanceThe stock is down -35% YTD compared to XBI -2%.
---
Ownership Overview
1.29% Insiders
34.43% Mutual Funds
0.20% Other Institutional Investors
37.11% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
XNCR FAQ
What was Xencor Inc’s price range in the past 12 months?
Xencor Inc lowest stock price was $12.54 and its highest was $27.24 in the past 12 months.
What is Xencor Inc’s market cap?
Xencor Inc’s market cap is $930.10M.
When is Xencor Inc’s upcoming earnings report date?
Xencor Inc’s upcoming earnings report date is May 08, 2025 which is in 44 days.
How were Xencor Inc’s earnings last quarter?
Xencor Inc released its earnings results on Feb 27, 2025. The company reported -$0.62 earnings per share for the quarter, beating the consensus estimate of -$0.784 by $0.164.
Is Xencor Inc overvalued?
According to Wall Street analysts Xencor Inc’s price is currently Undervalued.
Does Xencor Inc pay dividends?
Xencor Inc does not currently pay dividends.
What is Xencor Inc’s EPS estimate?
Xencor Inc’s EPS estimate is -0.58.
How many shares outstanding does Xencor Inc have?
Xencor Inc has 70,461,940 shares outstanding.
What happened to Xencor Inc’s price movement after its last earnings report?
Xencor Inc reported an EPS of -$0.62 in its last earnings report, beating expectations of -$0.784. Following the earnings report the stock price went up 2.537%.
Which hedge fund is a major shareholder of Xencor Inc?
Currently, no hedge funds are holding shares in XNCR
---
Xencor Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$29.56 (123.94% Upside)
$29.56 (123.94% Upside)
Blogger Sentiment
Bullish
XNCR Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 677.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $477.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 4.3%
Last 30 Days ▼ 13.5%
Last 30 Days ▼ 13.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-42.13%
12-Months-Change
Fundamentals
Return on Equity
-34.74%
Trailing 12-Months
Asset Growth
-1.37%
Trailing 12-Months
Company Description
Xencor Inc
Xencor, Inc. engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.
---
XNCR Stock 12 Month Forecast
Average Price Target
$29.56
▲(123.94% Upside)
Technical Analysis
Best Analysts Covering XNCR
1 Year
1 Year Success Rate
10/13 ratings generated profit
1 Year Average Return
+15.72%
reiterated a sell rating 26 days ago
Copying Peter Lawson's trades and holding each position for 1 Year would result in 76.92% of your transactions generating a profit, with an average return of +15.72% per trade.
---